公开(公告)号：EP4438037A1

公开(公告)日：2024-10-02

申请号：EP24179001.3

申请日：2022-01-27

Applicant: Priothera SAS ,  Priothera Limited

Inventor： BUCHER, Christoph ,  DERTSCHNIG, Simone

IPC: A61K31/00 ,  A61K9/00 ,  A61K31/137 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5377 ,  A61K38/13 ,  A61K31/13

CPC classification number: A61K31/137 ,  A61K31/00 ,  A61K31/397 ,  A61K31/4245 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61K31/5377 ,  A61K31/13 ,  A61K31/436 ,  A61K31/519

Abstract: The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from acute myelogenous leukemia (AML) and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.

公开(公告)号：EP4414032A2

公开(公告)日：2024-08-14

申请号：EP24169519.6

申请日：2016-09-22

Applicant: EyePoint Pharmaceuticals, Inc.

Inventor： PETERS, Kevin Gene

IPC: A61P27/06

CPC classification number: A61P27/06 ,  A61P27/02 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/497 ,  A61K31/496 ,  A61K31/513 ,  A61K31/433

Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.

公开(公告)号：EP3307257B1

公开(公告)日：2024-06-26

申请号：EP16725108.1

申请日：2016-05-24

IPC: A61K31/138 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/425 ,  A61K31/426 ,  A61K31/435 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/517 ,  A61K31/53 ,  A61K31/5375 ,  A61P35/00

CPC classification number: A61K45/06 ,  A61K31/138 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/425 ,  A61K31/426 ,  A61K31/435 ,  A61K31/47 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5375 ,  A61K31/4184 ,  A61P35/04 ,  A61K31/197 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/4152 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55

公开(公告)号：EP3653202B1

公开(公告)日：2024-05-01

申请号：EP18832644.1

申请日：2018-07-13

IPC: A61K9/20 ,  A61K9/28 ,  A61K31/426

CPC classification number: A61K31/426 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2018 ,  A61K9/2095

公开(公告)号：EP2786741B1

公开(公告)日：2018-12-26

申请号：EP12853735.4

申请日：2012-11-30

Applicant: AJINOMOTO CO., INC.

Inventor： TAKINO, Yoshinobu ,  OKURA, Fumie ,  KURODA, Shinji

IPC: A61K8/49 ,  A61K8/34 ,  A61K8/36 ,  A61K8/44 ,  A61K8/60 ,  A61K8/64 ,  A61K8/97 ,  A61K31/426 ,  A61P17/00 ,  A61P17/16 ,  A61P43/00 ,  A61Q19/02

CPC classification number: A61K8/49 ,  A61K8/361 ,  A61K8/368 ,  A61K8/44 ,  A61K8/445 ,  A61K8/4973 ,  A61K8/498 ,  A61K8/602 ,  A61K8/64 ,  A61K8/97 ,  A61K31/426 ,  A61Q19/02

Abstract: Provided is a cosmetic agent superior in a whitening effect (including prophylaxis and removal of pigmented spot) and having high safety. In addition, a superior melanin production suppressive agent is provided. A cosmetic agent or melanin production suppressive agent comprising (A) a cysteine derivative represented by the formula (I) or a salt thereof: wherein X and Y are each independently OR 1 or NHR 2 wherein R 1 and R 2 are each independently a hydrogen atom or a C 1-22 alkyl group; Z is a hydrogen atom or a C 1-22 alkyl group; and W is a C 1-22 alkyl group, a C 1-22 alkoxy group or a C 1-22 alkylamino group, and (B) a whitening agent.

公开(公告)号：EP3197449B1

公开(公告)日：2018-11-21

申请号：EP15790263.6

申请日：2015-09-23

Applicant: Universita' Degli Studi di Bari ,  Università degli Studi della Basilicata ,  Università di Pisa

Inventor： SVELTO, Maria ,  PROCINO, Giuseppe ,  CARMOSINO, Monica ,  DAL MONTE, Massimo ,  BAGNOLI, Paola

IPC: A61K31/426 ,  A61P3/10 ,  A61K31/137

CPC classification number: A61K31/426 ,  A61K31/137

Abstract: Object of the present invention is the use of selective agonists of beta-adrenergic type 3 receptors (BAR3) in the treatment of nephrogenic diabetes insipidus (NDI), in particular of X-linked nephrogenic diabetes insipidus (X-NDI).

公开(公告)号：EP3391883A1

公开(公告)日：2018-10-24

申请号：EP16875807.6

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  Rohto Pharmaceutical Co., Ltd.

Inventor： NIWA, Shinichiro ,  OGURA, Dai ,  MIZUNUMA, Hidemi ,  ARAI, Yoko ,  KUROSE, Takahiro ,  TAKAI, Yoshihiro ,  MITSUGUCHI, Yoko ,  MORIYA, Mariyo

IPC: A61K31/421 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/41 ,  A61K31/426 ,  A61K31/436 ,  A61K31/47 ,  A61K45/00 ,  A61P27/02 ,  A61P43/00

CPC classification number: G01N33/5023 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/41 ,  A61K31/421 ,  A61K31/426 ,  A61K31/436 ,  A61K31/47 ,  A61K45/00 ,  A61K45/06 ,  A61K2300/00 ,  A61P27/02

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

公开(公告)号：EP2775836B8

公开(公告)日：2018-10-24

申请号：EP11875217.9

申请日：2011-11-04

Applicant: CymaBay Therapeutics, Inc. ,  DiaTex, Inc.

Inventor： LAVAN, Brian Edward ,  SAHA, Gopal Chandra ,  ROBERTS, Brian K. ,  MCWHERTER, Charles A.

IPC: A61P19/06

CPC classification number: A61K31/216 ,  A61K31/047 ,  A61K31/09 ,  A61K31/192 ,  A61K31/195 ,  A61K31/343 ,  A61K31/352 ,  A61K31/40 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/573 ,  A61K31/6615 ,  A61K45/06 ,  A61P19/06 ,  A61K2300/00

Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (-)- halofenate, (-)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.

公开(公告)号：EP3373958A1

公开(公告)日：2018-09-19

申请号：EP16865148.7

申请日：2016-11-11

Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Inventor： BARDAG-GORCE, Fawzia

IPC: A61K38/55 ,  A61K31/00 ,  A61K38/16

CPC classification number: A61K31/7048 ,  A61K31/222 ,  A61K31/336 ,  A61K31/4015 ,  A61K31/407 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/69

Abstract: Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.

公开(公告)号：EP2977056B1

公开(公告)日：2018-09-12

申请号：EP15171056.3

申请日：2015-06-08

Applicant: Grifols Worldwide Operations Limited

Inventor： ROSS, DAVID A. ,  CRUMRINE, RALPH CHRISTIAN

IPC: A61P9/10 ,  A61K38/40 ,  A61K45/06 ,  A61K31/16 ,  A61K31/198 ,  A61K31/4196 ,  A61K31/4412 ,  A61P25/28 ,  A61K31/4704 ,  A61K31/223 ,  A61K31/426 ,  A61K31/472 ,  A61P39/04

CPC classification number: A61K38/40 ,  A61K31/16 ,  A61K31/164 ,  A61K31/198 ,  A61K31/223 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/4412 ,  A61K31/4704 ,  A61K31/472 ,  A61K45/06 ,  A61P9/10 ,  A61P25/28 ,  A61P39/04 ,  A61K2300/00

Abstract: The present invention relates to transferrin, possibly in combination with an iron-chelator (e.g. deferoxamine) or a PHD2 enzyme inhibitor, for use in the treatment of Hypoxia Inducible Factor (HIF)-related conditions, in particular associated with organ transplantation, ischemia, oxygen deprivation, interruption of blood during surgical intervention, or neurodegenerative disorders.